PERSPECTIVE THERAPEUTICS INC
CATXNYSE AMERICANTrading Snapshot
- Day Range
- $1.07 β $1.25
- 52-Week Range
- $1.06 β $6.16
- Volume (shares)
- 325,734
- Avg Volume (shares)
- β
- Shares Outstanding
- 114.2M
- Next Earnings
- 2026-11-09
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- $81,000
- P/E Ratio
- -0.8
- P/S Ratio
- 389.9x
- EPS (TTM)
- $-1.58
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.2%
PERSPECTIVE THERAPEUTICS INC
CATXAbout PERSPECTIVE THERAPEUTICS INC
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle β from development and manufacturing to sales and marketing β of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates
News unavailable.